Ken Griffin Adverum Biotechnologies, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$0.75 - $1.26 $1,875 - $3,150
2,500 Added 1250.0%
2,700 $2,000
Q3 2023

Nov 14, 2023
BUY
$1.5 - $2.33 $300 - $466
200 New
200 $0
Q3 2022

Nov 14, 2022
SELL
$0.96 - $9.68 $384 - $3,872
-400 Reduced 3.6%
10,700 $10,000

Others Institutions Holding ADVM

# of Institutions
3
Shares Held
524K
Call Options Held
0
Put Options Held
0
View Full List

About Adverum Biotechnologies, Inc.

ADVM Quotes by TradingView
  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email